Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment.
Amnestic mild cognitive impairment (aMCI) is considered a prodromal stage of Alzheimer's disease (AD). We measured plasma levels of amyloid-beta40 (Abeta40) and Abeta42 in 191 subjects with aMCI. Seventy-nine of them were clinically followed for two years. In the total cohort of aMCI cases, the average level of Abeta42, as well as the Abeta42/Abeta40 ratio, was significantly higher than those of the 102 cognitively normal age-matched subjects. The aMCI cases that converted to probable AD within 2 years had higher levels of Abeta42 and, to a lesser extent, Abeta40 than the stable cases. However the large variability of measured values indicates that plasma Abeta is not a suitable marker of incipient AD.
Cammarata
Sergio
S
Department of Neurology, Galliera Hospital, Genova, Italy.
Borghi
Roberta
R
Giliberto
Luca
L
Pardini
Matteo
M
Pollero
Valeria
V
Novello
Cristina
C
Fornaro
Michele
M
Vitali
Antonella
A
Bracco
Laura
L
Caltagirone
Carlo
C
Bossù
Paola
P
Odetti
Patrizio
P
Tabaton
Massimo
M
D000368:Aged; D000647:Amnesia / Q000097:blood* / Q000150:complications; D016229:Amyloid beta-Peptides / Q000097:blood*; D003072:Cognition Disorders / Q000097:blood* / Q000150:complications; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008609:Mental Status Schedule; D009483:Neuropsychological Tests; D010446:Peptide Fragments / Q000097:blood*; D018709:Statistics, Nonparametric
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)